Spectranetics Completes Acquisition of Stellarex(TM) Drug Coated Balloon Assets From Covidien
January 27, 2015 08:20 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Jan. 27, 2015 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced it has completed the acquisition of Covidien's Stellarex™ drug coated...
Spectranetics to Present at the J.P. Morgan 33rd Annual Healthcare Conference
December 29, 2014 16:02 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Dec. 29, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be presenting at the J.P. Morgan 33rd Annual Healthcare...
Spectranetics Outlines Growth Opportunities at Analyst & Investor Meeting
December 04, 2014 07:30 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Dec. 4, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) will provide an overview of several transformative growth drivers within its Vascular Intervention...
Spectranetics to Host Investor & Analyst Meeting
November 17, 2014 16:01 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Nov. 17, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) will host an Analyst & Investor meeting in New York City on Thursday, December 4, 2014...
Spectranetics to Participate in Upcoming Investor Conferences
November 05, 2014 16:01 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Nov. 5, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be participating in three upcoming investor...
Spectranetics to Acquire Stellarex(TM) Drug Coated Balloon Assets From Covidien
November 02, 2014 19:00 ET
|
The Spectranetics Corporation
Conference Call Monday at 8:30 a.m. ET
Expands Spectranetics' portfolio of solutions to treat complex vascular conditions in projected $700 million drug coated balloon segment
COLORADO...
Spectranetics Achieves Third Quarter 2014 Revenue of $58.8 Million
October 23, 2014 16:01 ET
|
The Spectranetics Corporation
FDA Clearance of In-Stent Restenosis Indication Achieved;
AngioScore Integration On Track
2014 Outlook Revised Upward
COLORADO SPRINGS, Colo., Oct. 23, 2014 (GLOBE NEWSWIRE) -- The...
Spectranetics to Hold 2014 Third Quarter Financial Results Conference Call on October 23
October 09, 2014 16:01 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Oct. 9, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release 2014 third quarter financial results after market...
EXCITE ISR Proves Superiority in Safety, Efficacy of Laser Atherectomy With PTA vs. PTA Alone; Data Presented at TCT 2014
September 16, 2014 11:42 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Sept. 16, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that Eric Dippel, MD, at Transcatheter Cardiovascular Therapeutics (TCT), the...
Spectranetics' EXCITE ISR Data to Be Presented at Transcatheter Cardiovascular Therapeutics (TCT) Late-Breaking Clinical Trial Session in Washington, D.C.
September 10, 2014 09:29 ET
|
The Spectranetics Corporation
COLORADO SPRINGS, Colo., Sept. 10, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that data from EXCITE ISR will be presented as a late-breaking clinical trial at...